BCV
VRTX icon

Banque Cantonale Vaudoise’s Vertex Pharmaceuticals VRTX Stock Holding History

Banque Cantonale Vaudoise’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.99M Sell
8,927
-2,149
-19% -$1M 0.15% 132
2025
Q4 		$5.02M Buy
11,076
+954
+9% +$411K 0.18% 106
2025
Q3 		$3.96M Sell
10,122
-407
-4% -$170K 0.15% 125
2025
Q2 		$4.69M Buy
10,529
+231
+2% +$106K 0.19% 99
2025
Q1 		$4.99M Buy
+10,298
New +$4.8M 0.22% 86
2024
Q3 		$5.2M Buy
11,182
+8,720
+354% +$4.19M 0.21% 107
2024
Q2 		$1.15M Buy
2,462
+1,256
+104% +$545K 0.05% 324
2024
Q1 		$504K Sell
1,206
-4,457
-79% -$1.88M 0.02% 426
2023
Q4 		$2.3M Sell
5,663
-1,402
-20% -$518K 0.1% 211
2023
Q3 		$2.46M Buy
7,065
+861
+14% +$301K 0.12% 135
2023
Q2 		$2.18M Sell
6,204
-555
-8% -$187K 0.1% 176
2023
Q1 		$2.13M Buy
6,759
+1,600
+31% +$480K 0.1% 193
2022
Q4 		$1.49M Sell
5,159
-2,819
-35% -$859K 0.08% 236
2022
Q3 		$2.31M Sell
7,978
-478
-6% -$138K 0.13% 149
2022
Q2 		$2.38M Buy
8,456
+320
+4% +$85.7K 0.12% 152
2022
Q1 		$2.12M Buy
8,136
+1,955
+32% +$464K 0.09% 216
2021
Q4 		$1.36M Sell
6,181
-8,088
-57% -$1.57M 0.05% 343
2021
Q3 		$2.59M Sell
14,269
-3,042
-18% -$594K 0.11% 178
2021
Q2 		$3.49M Buy
17,311
+4,930
+40% +$1.03M 0.16% 137
2021
Q1 		$2.66M Sell
12,381
-239
-2% -$52.5K 0.14% 153
2020
Q4 		$2.98M Buy
12,620
+296
+2% +$67.9K 0.17% 128
2020
Q3 		$3.35M Sell
12,324
-7,197
-37% -$1.99M 0.22% 98
2020
Q2 		$5.67M Buy
19,521
+9,673
+98% +$2.62M 0.41% 47
2020
Q1 		$2.34M Sell
9,848
-60
-0.6% -$13.8K 0.2% 102
2019
Q4 		$2.17M Buy
+9,908
New +$2.01M 0.15% 151

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Banque Cantonale Vaudoise's VRTX Position: Q1 2026 in Review

Banque Cantonale Vaudoise reduced its Vertex Pharmaceuticals (VRTX) stake by 19% in Q1 2026, selling an estimated $1M and leaving 8,927 shares worth $3.99M. The position accounts for 0.15% of the portfolio, ranked #132.

Banque Cantonale Vaudoise first reported a position in VRTX in Q4 2019 and has held it in 25 quarters since. The position peaked at $5.67M in Q2 2020. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Banque Cantonale Vaudoise held 8,927 shares of Vertex Pharmaceuticals worth $3.99M as of Q1 2026.
  • Banque Cantonale Vaudoise sold 2,149 Vertex Pharmaceuticals shares in Q1 2026, an estimated $1M.
  • Vertex Pharmaceuticals made up 0.15% of Banque Cantonale Vaudoise's portfolio in Q1 2026, its #132 holding.
  • Banque Cantonale Vaudoise first reported a position in Vertex Pharmaceuticals in Q4 2019 and has held it in 25 quarters since.
  • Banque Cantonale Vaudoise's Vertex Pharmaceuticals position peaked at $5.67M in Q2 2020.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Banque Cantonale Vaudoise's 13F filing for Q1 2026, filed 20 Apr 2026.